DEMA Stock Overview
Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Demant A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.43.62 |
| 52 Week High | kr.49.76 |
| 52 Week Low | kr.34.04 |
| Beta | 0.91 |
| 1 Month Change | -2.07% |
| 3 Month Change | 2.15% |
| 1 Year Change | 9.35% |
| 3 Year Change | 0% |
| 5 Year Change | n/a |
| Change since IPO | 72.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| DEMA | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | -0.4% | 0.3% | 0.9% |
| 1Y | 9.4% | -0.8% | 6.7% |
Return vs Industry: DEMA exceeded the Austrian Medical Equipment industry which returned -0.8% over the past year.
Return vs Market: DEMA exceeded the Austrian Market which returned 6.7% over the past year.
Price Volatility
| DEMA volatility | |
|---|---|
| DEMA Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.1% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: DEMA has not had significant price volatility in the past 3 months.
Volatility Over Time: DEMA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1904 | 21,623 | Søren Nielsen | www.demant.com |
Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services.
Demant A/S Fundamentals Summary
| DEMA fundamental statistics | |
|---|---|
| Market cap | €9.49b |
| Earnings (TTM) | €342.21m |
| Revenue (TTM) | €3.01b |
27.7x
P/E Ratio3.2x
P/S RatioIs DEMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DEMA income statement (TTM) | |
|---|---|
| Revenue | kr.22.44b |
| Cost of Revenue | kr.5.90b |
| Gross Profit | kr.16.54b |
| Other Expenses | kr.13.99b |
| Earnings | kr.2.55b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | 11.72 |
| Gross Margin | 73.72% |
| Net Profit Margin | 11.37% |
| Debt/Equity Ratio | 126.0% |
How did DEMA perform over the long term?
See historical performance and comparison